Fabris F - Search Results

1

Hydroxyurea in old patients with essential thrombocythemia.

Randi ML, Ruzzon E, Piccoli A, Tezza F, Scapin M, Scandellari R, Fabris F. Randi ML, et al. Among authors: fabris f. Aging Clin Exp Res. 2008 Aug;20(4):376-80. doi: 10.1007/BF03324871. Aging Clin Exp Res. 2008. PMID: 18852553

2

Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.

Randi ML, Fabris F, Ruzzon E, Pacquola E, Cella G, Girolami A. Randi ML, et al. Among authors: fabris f. Haematologica. 2002 Nov;87(11):1180-4. Haematologica. 2002. PMID: 12414348

3

Toxicity and side effects of hydroxyurea used for primary thrombocythemia.

Randi ML, Ruzzon E, Tezza F, Luzzatto G, Fabris F. Randi ML, et al. Among authors: fabris f. Platelets. 2005 May-Jun;16(3-4):181-4. doi: 10.1080/09537100400020179. Platelets. 2005. PMID: 16011962 Free article.

4

Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature.

Ruzzon E, Randi ML, Tezza F, Luzzatto G, Scandellari R, Fabris F. Ruzzon E, et al. Among authors: fabris f. Aging Clin Exp Res. 2006 Jun;18(3):187-90. doi: 10.1007/BF03324647. Aging Clin Exp Res. 2006. PMID: 16804363 Review.

5

Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative.

Randi ML, Putti MC, Scapin M, Pacquola E, Tucci F, Micalizzi C, Zanesco L, Fabris F. Randi ML, et al. Among authors: fabris f. Blood. 2006 Nov 15;108(10):3600-2. doi: 10.1182/blood-2006-04-014746. Epub 2006 Jul 18. Blood. 2006. PMID: 16849644 Free article.

6

Essential thrombocythemia: past and present.

Fabris F, Randi ML. Fabris F, et al. Intern Emerg Med. 2009 Oct;4(5):381-8. doi: 10.1007/s11739-009-0284-x. Epub 2009 Jul 28. Intern Emerg Med. 2009. PMID: 19636672 Review.

7

Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.

Randi ML, Brunati AM, Scapin M, Frasson M, Deana R, Magrin E, Fabris F, Donella-Deana A. Randi ML, et al. Among authors: fabris f. Blood. 2010 Jan 21;115(3):667-76. doi: 10.1182/blood-2008-12-196535. Epub 2009 Nov 12. Blood. 2010. PMID: 19965650 Free article.

8

JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia.

Randi ML, Ruzzon E, Tezza F, Scapin M, Duner E, Scandellari R, Fabris F. Randi ML, et al. Among authors: fabris f. Aging Clin Exp Res. 2011 Feb;23(1):17-21. doi: 10.1007/BF03324948. Aging Clin Exp Res. 2011. PMID: 21499015

9

Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.

Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F. Randi ML, et al. Among authors: fabris f. Haematologica. 2005 Feb;90(2):261-2. Haematologica. 2005. PMID: 15710584

10

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation.

Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, Scapin M, Arcaini L, Tezza F, Moratti R, Pascutto C, Fabris F, Morra E, Cazzola M, Lazzarino M. Passamonti F, et al. Among authors: fabris f. Blood. 2007 Jul 15;110(2):485-9. doi: 10.1182/blood-2007-01-071068. Epub 2007 Apr 10. Blood. 2007. PMID: 17426257 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

581 results

Search Page

Filters